Merck & Company
West Coast Innovation Hub
499 Illinois St. Suite 100
About Merck & Company
Network with Merck representatives at the 2018 Biotech Bay and Genetown Talent Connects. Learn more here
Merck and Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Merck discovers, develops, manufactures, and markets vaccines and medicines in over 20 therapeutic categories directly and through its joint ventures. Our mission is to provide society with superior products and services by developing innovations and solutions that improve the quality of life. The focus of research at Merck is on innovation in all areas of drug research and development, working on programs to satisfy unmet medical needs.
With approximately 60,000 employees, Merck conducts research at ten major research centers in the United States, Europe, and Japan, manufactures products in 30 facilities, and sells products in approximately 150 countries.
At Merck, our strategy for growth is based on breakthrough research - both internal and external through partnerships - and demonstrating the value of our medicines to patients, payers, and providers. Worldwide sales in 2004 were $22.9 billion. Merck continues to invest heavily in research and development, with R&D spending in 2005 estimated to be approximately $4 billion.
Merck's product line includes a broad portfolio of highly innovative prescription products in important therapeutic areas. Human health products include medicines to treat high blood pressure, congestive heart failure, elevated cholesterol levels, osteoporosis, benign prostatic hypertrophy, arthritis, pain, migraine, glaucoma, gastrointestinal ulcers, infectious diseases (antibiotic, anti-fungal, and antiviral agents), and vaccines to prevent childhood diseases and hepatitis A and B.
At Merck, we are strongly committed to partnership success. We have a long tradition of successful partnerships. Alliances with innovative partners are an integral part of our long-term business and research strategy. More than one-third of our sales are from alliance products and patents, including some of our biggest growth drivers.
Our vision is to create a "virtual lab" - the pursuit of the best scientific programs from both internal research and external collaborations. This approach will accelerate the successful development and commercialization of breakthrough discoveries that can bring meaningful improvements to patients' lives.
Our focus is seeking alliances for new NCE's and biological entities as product candidates for development. We are open to basic research collaborations and early research technologies as well.
Merck welcomes partnerships touching virtually all human health therapeutic areas that address unmet needs for patients, as well as technologies that will enhance the productivity of our research laboratories. Therapeutic areas of particular interest include cancer, central nervous system disorders, diabetes, and obesity. Also of interest include the following: anti-infectives, anti-virals, cardiovascular diseases, gastrointestinal diseases, immunology, new vaccine technology, ophthalmics, osteoporosis, pain, respiratory, vaccines, and platform research technology.
To contact Merck about a licensing opportunity, please contact Chief Licensing Officer, Merck & Co., Inc., One Merck Drive, P.O. Box 100, Whitehouse Station, NJ 08889 USA; Fax: 908-735-1201. Please provide a brief, non-confidential overview of your discovery with sufficient data to allow a preliminary scientific review.
For further information, please visit our website at http://www.merck.com/licensing/
90 articles with Merck & Company
Federal court judge orders Merck to repay $2.5 Billion to Gilead in overturned patent decision.
The U.S. Food and Drug Administration (FDA) approved AstraZeneca’s Imfinzi to treat patients with unresectable Stage III non-small cell lung cancer (NSCLC).
Despite the recent dismal news regarding Alzheimer’s drug development, the U.S. Food and Drug Administration (FDA) recently proposed new guidelines for developing drugs for the disease.
Since 2013, Dr. Perlmutter has served as executive vice president of Merck and president of Merck Research Laboratories.
1/17/2018Despite some safety concerns such as severe diarrhea, the FDA approved Puma's breast cancer drug Nerlynx in July 2017.
Amgen's migraine drug Aimovig continues to impress with its efficacy in late-stage studies.
Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer.
Here is a look at key takeaways from presentations made by four major pharma and biotech stocks at the annual J.P. Morgan healthcare conference.
A look at the lucky drugs that have been hailed a breakthrough by the FDA.
Merck’s Keytruda Significantly Improved Recurrence-Free Survival Compared to Placebo as Adjuvant ...
1/8/2018The safety profile of Keytruda in this trial was consistent with that observed in previously reported studies involving patients with advanced melanoma.
Rounding out the top five companies behind J&J and Sanofi are AbbVie, Celgene and Merck.
New and Updated Data for Merck’s KEYTRUDA (pembrolizumab) and Updated Data on LYNPARZA (olaparib) in Multiple Breast Cancer Subtypes to Be Presented at the 2017 San Antonio Breast Cancer Symposium (SABCS)
In addition to the presentation of KEYTRUDA data at SABCS, updated data on LYNPARZA being co-developed and co-commercialized with AstraZeneca, will be presented.
Merck donates MECTIZAN (ivermectin) for onchocerciasis (river blindness) in all affected areas (Latin America, Africa, Yemen) and for LF in African countries where it co-exists with river blindness.
11/30/2017As 2017 comes to a close, 40 drugs have been approved so far, with the record being in 2015, when 46 drugs were approved.
The Board also authorized an additional $10 billion of treasury stock purchases with no time limit for completion.
11/27/2017The move is in part related to Brexit, the UK's exit from the European Union.
Researchers are making great headway against cancer, even though it's currently still the second-leading cause of death in the U.S.
Immunovaccine Announces Regulatory Clearance for Phase II Clinical Trial Evaluating DPX-Survivac in Combination With Merck’s Checkpoint Inhibitor Pembrolizumab in DLBCL
This trial is designed to evaluate the safety and efficacy of Immunovaccine’s lead candidate along with Merck’s pembrolizumab and low-dose cyclophosphamide in this patient population.
Merck released its third-quarter financial results today, and along with it a hint--just a hint--that there might be some M&A deals in the future.
10/25/2017Incyte has been at the forefront of the IDO race with its candidate epacadostat.